TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00405756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide: Double-blind Induction
Description: Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion
Study: NCT03573986

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: positron emission tomography (PET/CT).
Description: PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
Study: NCT02372669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan nerve tube in addition to gold standard therapy
Description: Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gold standard Primary microsurgical repair
Description: Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gold standard Primary microsurgical repair
Description: Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
Study: NCT04230837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inmediate abutment height
Description: The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inmediate abutment height
Description: The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.
Study: NCT03146988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RGB-02 or Neulasta® (pegfilgrastim)
Description: Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGB-02 or Neulasta® (pegfilgrastim)
Description: Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
Study: NCT02220270

Intervention type: DEVICE
Intervention: ASD and PDA closure
Study: NCT00405756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion
Study: NCT03905785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Samarthan
Description: Samarthan intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
Study: NCT04346472

Intervention type: OTHER
Intervention: Repeated Measurements of the relative regional cerebral blood volume
Description: Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
Study: NCT04918212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fabulous Stent Graft System
Description: All patients received endovascular surgery using fabulous stent graft system
Study: NCT03127657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cock's comb extract 0.01%
Description: Applied topically twice daily for 12 weeks
Study: NCT03858491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).
Study: NCT04145778

Intervention type: OTHER
Intervention: 6-minute walk test
Description: The 6-minute walk test is performed as part of routine practice for patients with BMDS to assess patients' overall endurance. In order to compare patients' global endurance with controls, this walking test will also be offered to 50 of the healthy subjects already recruited in the study.

Intervention type: OTHER
Intervention: 6-minute walk test
Description: The 6-minute walk test is performed as part of routine practice for patients with BMDS to assess patients' overall endurance. In order to compare patients' global endurance with controls, this walking test will also be offered to 50 of the healthy subjects already recruited in the study.
Study: NCT01613521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE-MRI and 18F-FMISO PET
Description: DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
Study: NCT03462316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
Description: NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
Study: NCT00405756

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide: Double-blind Maintenance
Description: Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide: Open-label
Description: Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
Study: NCT03006913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person
Description: At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: By phone
Description: Patients in the phone arm will receive a scheduled call at their home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: By video
Description: Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
Study: NCT03278990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Value Affirmation and Future Selves Combination
Description: Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control writing exercise
Description: In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
Study: NCT03291210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal inspired oxygen fraction
Description: receives inspired oxygen fraction of 0.3
Study: NCT00405756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide: Open-label
Description: Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide: Open-label
Description: Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
Study: NCT04035408

Intervention type: OTHER
Intervention: Skin health assessment
Description: Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
Study: NCT02247726

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo (0.5mL injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSV F vaccine (0.5mL injection)
Study: NCT03291210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high inspired oxygen fraction
Description: receives inspired oxygen fraction of 0.8
Study: NCT04049942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation group
Description: Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training group
Description: Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
Study: NCT04014075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
Study: NCT02622828

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Participant-identified community based activity
Description: The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
Study: NCT02200848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Ibrutinib, Rituximab
Description: Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
Study: NCT05568251

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Participants will be administered Game of Dice Task concurrent with the tDCS session

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: Participants will be administered Game of Dice Task concurrent with the tDCS session
Study: NCT02515409

Intervention type: DEVICE
Intervention: HHHFNC
Description: After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.

Intervention type: DEVICE
Intervention: CPAP
Description: CPAP, as a first line treatment in OSAS.
Study: NCT01254435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Recording of colonoscopic extubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Recording of colonoscopic extubation
Study: NCT00666757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 30-120 milligrams (mgs) orally daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 20-80 mgs orally daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: 20-40 mgs orally daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: 20-50 mgs orally daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: 50-200 mgs orally daily for 12 weeks
Study: NCT00802399

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Partial Lacrimal Punctual Occlusion
Description: Cauterization of the edge of all lacrimal punctum was carried out in all patients
Study: NCT01044602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory evaluations, sleep study
Description: Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory evaluations, sleep study
Description: Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Management
Description: Standard of care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass surgery
Description: Surgical treatment.
Study: NCT01609920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadofosveset enhanced MRL of axillary lymph nodes
Description: A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
Study: NCT01957462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test V
Description: Coloplast Test product V is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test V
Description: Coloplast Test product V is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test X
Description: Coloplast Test X is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test X
Description: Coloplast Test X is a newly developed 1-piece ostomy appliance
Study: NCT01172951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: 75g anhydrous glucose powder mixed with 100mls water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: 75g anhydrous glucose powder mixed with 100mls water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral lipid tolerance test
Description: 150ml drink composed of 2 commercially available high fat products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral lipid tolerance test
Description: 150ml drink composed of 2 commercially available high fat products
Study: NCT03434041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: Participants will self-administer 56 mg of esketamine as intranasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Description: Participants will self-administer 84 mg of esketamine as intranasal spray.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will self-administer matching placebo as intranasal spray.
Study: NCT01076413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skill based exercise
Description: 2 times per week for 12 weeks Pre gait and gait activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic conditioning
Description: 2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
Study: NCT00527982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 600 mg by mouth daily for a total of 12 months.
Study: NCT03410121

Intervention type: DEVICE
Group type: OTHER
Intervention: IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108.
Description: Implantation of intravenous medical device in thoracic location

Intervention type: DEVICE
Group type: OTHER
Intervention: Vital Port®Minititanium
Description: Implantation of intravenous medical device in humeral location
Study: NCT03079219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: Aprepitant
Description: Day 1: 125mg QD; Day 2 to Day 3: 80mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: Ondansetron
Description: Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: Dexamethasone
Description: Day 1: 12mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug: Olanzapine
Description: Day 1 to Day 5: 10mg QD